Capital Investment Advisory Services LLC Raises Stock Holdings in Pfizer Inc. (NYSE:PFE)

Capital Investment Advisory Services LLC boosted its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 5.4% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 211,337 shares of the biopharmaceutical company's stock after buying an additional 10,767 shares during the period. Capital Investment Advisory Services LLC's holdings in Pfizer were worth $5,355,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Argyle Capital Management LLC raised its holdings in Pfizer by 2.9% in the 1st quarter. Argyle Capital Management LLC now owns 138,706 shares of the biopharmaceutical company's stock valued at $3,515,000 after buying an additional 3,900 shares during the period. Brookstone Capital Management grew its position in Pfizer by 7.0% in the 1st quarter. Brookstone Capital Management now owns 116,746 shares of the biopharmaceutical company's stock valued at $2,958,000 after acquiring an additional 7,593 shares in the last quarter. Huntleigh Advisors Inc. grew its position in Pfizer by 1.2% in the 1st quarter. Huntleigh Advisors Inc. now owns 58,547 shares of the biopharmaceutical company's stock valued at $1,484,000 after acquiring an additional 713 shares in the last quarter. Deroy & Devereaux Private Investment Counsel Inc. grew its position in Pfizer by 9.8% in the 1st quarter. Deroy & Devereaux Private Investment Counsel Inc. now owns 8,375 shares of the biopharmaceutical company's stock valued at $212,000 after acquiring an additional 750 shares in the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. acquired a new position in Pfizer in the 1st quarter valued at about $223,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have weighed in on PFE. Morgan Stanley lifted their target price on Pfizer from $31.00 to $32.00 and gave the company an "equal weight" rating in a research report on Wednesday, April 30th. TD Cowen dropped their target price on Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a research report on Tuesday, April 22nd. Wolfe Research lifted their target price on Pfizer from $22.00 to $23.00 and gave the company an "underperform" rating in a research report on Wednesday, April 30th. Berenberg Bank dropped their target price on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research report on Thursday, May 29th. Finally, Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $28.55.

Pfizer Stock Up 0.5%

PFE stock traded up $0.13 during trading on Friday, hitting $25.45. 27,104,580 shares of the company's stock were exchanged, compared to its average volume of 41,722,894. The business has a 50-day moving average price of $23.72 and a two-hundred day moving average price of $24.82. The stock has a market capitalization of $144.66 billion, a price-to-earnings ratio of 18.44, a PEG ratio of 0.92 and a beta of 0.58. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The firm's revenue was down 7.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.82 earnings per share. As a group, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.76%. The ex-dividend date is Friday, July 25th. Pfizer's payout ratio is 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.